EPT Disclosure

RNS Number:4771E
Cazenove
13 June 2006

                                                                    FORM 38.5(a)



                 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
                      WITH RECOGNISED INTERMEDIARY STATUS
                      DEALING IN A CLIENT-SERVING CAPACITY
                      (Rule 38.5(a) of the Takeover Code)



1.         KEY INFORMATION


Name of exempt principal trader                Cazenove

Company dealt in                               Cambridge Antibody Technology
                                               Group

Class of relevant security to which the        Ordinary 0.10p
dealings being disclosed relate (Note 1)

Date of dealing                                12th June 2006



2.         DEALINGS (Note 2)


(a)        Purchases and sales


Total number of securities          Highest price paid    Lowest price paid
purchased                           (Note 3)              (Note 3)

9,286                               #13.085p              #13.085p



Total number of securities   Highest price received    Lowest price received
sold                         (Note 3)                  (Note 3)

9,286                        #13.085p                  #13.08p



(b)        Derivatives transactions (other than options)


Product  name,    Long/short        Number of securities  Price per unit
e.g. CFD          (Note 4)          (Note 5)              (Note 3)


(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying


Product   Writing,     Number of     Exercise  Type, e.g.    Expiry  Option
name,e.g  selling,     securities to price     American,     date    moneypaid/
call      purchasing,  which the               European etc.         received
option    varying etc  option                                        per unit
                       relates (Note                                 (Note 3)
                       5)


(ii)        Exercising


Product name, e.g.   Number of securities            Exercise price per unit
call option                                          (Note 3)


3.         OTHER INFORMATION



Agreements, arrangements or understandings relating to options or derivatives


Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced.  If none, this should be
stated.



..............................................................................



..............................................................................






Date of disclosure                                13th June 2006

Contact name                                      Barry Page

Telephone number                                  0207 155 5907

Name of offeree/offeror with which connected      AstraZeneca Plc

Nature of connection (Note 6)                     Acting for AstraZeneca Plc





Notes



The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

EMMAKNKDKBKDOAD